Hernia, VentralNCT00472134
Laparoscopic Ventral Hernia Repair With Elastomeric Pain Pump
A study testing bupivacaine and On-Q PainBuster pump in people with Hernia, Ventral, run by University Hospitals Cleveland Medical Center at 1 site in United States.
Trial summary
The purpose of this study is to determine the effects of a local anesthetic dispensed via a tiny catheter device, called the ON-Q PainBuster pump, placed during surgery on top of the mesh used in the laparoscopic repair of ventral hernias. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hernia, Ventral
- What is being tested?
- bupivacaine and On-Q PainBuster pump
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2005to Dec 2007
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Laparoscopic ventral hernia repair
- Consent obtained
Who cannot join
- Under 18 years
- Allergic to Bupivacaine
- significant liver or renal disease
- Contraindication to PCA
- Current daily opioid usage
- History of substance abuse disorders
- Dx of chronic pain syndrome
- Daily usage of NSAIDs or COX 2 inhibitors
Trial locations and contacts
1 site in 1 country.
United States1 site
University Hospitals of Cleveland
Cleveland, Ohio, 44106
About this study
Official title: Prospective, Randomized, Double-blind Trial of Continuous Infusion of 0.5% Bupivacaine be Elastomeric Pump for Prospective Pain Management After Laparoscopic Ventral Hernia Repair.
The purpose of this study is to determine the effects of a local anesthetic dispensed via a tiny catheter device, called the ON-Q PainBuster pump, placed during surgery on top of the mesh used in the laparoscopic repair of ventral hernias. The goals are:
- reducing postoperative pain from this procedure
- decreasing length of hospital stay
- reducing or eliminating amount of post-operative narcotics used
Read the detailed description
One outcome of the greater than 2 million abdominal operations performed in the United States each year is an incisional hernia rate of 3% to 20%. As a result, approximately 150,000 ventral hernia repairs are performed annually. The increasing number of incisional hernias merely reflects the evolution of surgery with the ability to perform larger abdominal operations such as aortic surgery and colectomy. Primary tissue repairs have had unacceptable rates of recurrence when used for larger defects. The introduction of prosthetic biomaterials revolutionized hernia surgery with the concept of a tension-free repair. The subsequent rate of recurrence has been lowered to less than 10%. However, the required dissection of wide areas of soft tissue for mesh placement contribute to an incidence of wound infections and wound-related complications of 12% or greater. These problems were part of the impetus to develop minimally invasive techniques for ventral herniorrhaphy.
The laparoscopic repair of ventral hernias is rapidly evolving with patient and surgeon interest in less morbid herniorrhaphies and the appeal of minimally invasive surgery. The technique is based on the open, preperitoneal repair described by Rives and Stoppa. The placement of a large mesh in the preperitoneal location allows for an even distribution of forces along the surface area of the mesh, which may account for the strength of the repair and the decreased recurrence rates associated with it. The minimally invasive approach embraces the concept that a retromuscular mesh repair may be more durable, although the mesh is placed one layer deeper on an intact peritoneum in comparison to the open technique. The technique incorporates other fundamental components of the open repair such as wide mesh overlap of the defect and the use of transabdominal fixation sutures and spiral tacks to secure the mesh.
While the laparoscopic approach to ventral hernia repair has been documented as safe and effective, with low recurrence rates and minimal patient morbidity, some patients complain of significant post-operative pain for up to 1-3 months after surgery. The exact cause of this postoperative discomfort has not been clearly elucidated. Several hypotheses exist. Some feel that the extensive adhesiolysis required for incisional hernia repair causes significant peritoneal irritation that is exacerbated with the placement of intraperitoneal mesh. Others implicate the spiral tacks placed through the mesh into the peritoneum as sources of persistent discomfort. While others feel that the transabdominal fixation sutures are the localizing site for the accompanying postoperative pain. Transabdominal suture site pain after laparoscopic ventral hernia repair is not uncommon, and occurred in 23% of patients in one series.8 The transabdominal fixation suture sites are those incisions where sutures are placed to secure the mesh placed during laparoscopic ventral hernia repair to the anterior abdominal wall. The sutures are placed in a "clockwise" manner approximately every 4 to 5 cm at the periphery of the mesh as well as 5 mm spiral tacks to hold it in place until fibrocollagenous ingrowth secures the mesh to the abdominal wall. This persistent abdominal pain has been documented as a minor long-term complication resulting from laparoscopic ventral hernia repair, but it can be troublesome for patients in the immediate postoperative period.
The most effective method for managing this postoperative pain has not been defined.
The goal of postoperative care is to minimize the amount of pain a patient experiences following surgery and to help the patient make a quick recovery that leads to a shorter hospital stay free of complications and an earlier return to self-reliance. The most common treatment for pain after operation is opioid analgesic drug administration. Opioids are associated with undesirable side effects such as respiratory depression, nausea and vomiting, itching, increased duration of postoperative ileus, and delay in discharge. These side effects can be decreased with a reduction in the amount of opioid drugs utilized. Additionally, systemic narcotics may not optimize pain management in a specific region of the body because of its centralized effect. This may lead to a decreased mentation, reduced mobility, and a slower return to normal activities. Because a reduction of the daily consumption of narcotics is often associated with a decrease in analgesia, many other treatments for postoperative pain have been evaluated. For example, epidural analgesia is effective but the catheter needs to be placed preoperatively, is fairly invasive method, and the maintenance of the epidural treatment can be time consuming and expensive. Many studies have found clinical pain management benefits to the use of local analgesia, as measured by the use of less post-operative pain medication and more favorable ratings on pain intensity scales. Recently, a new method of delivering continuous wound infiltration with a solution of local anesthetic through an indwelling irrigation apparatus has been used in an attempt to reduce early postoperative discomfort in patients after thoracotomy, donor nephrectomy, and open inguinal hernia repair. These prospective randomized double blind studies universally report decreased postoperative discomfort and limited usage of opioids with the usage of these novel catheters.
In this study, the goal is to minimize postoperative pain so that post-operative narcotic requirements will be unnecessary or required less frequently. The infusion of a local anesthetic immediately following the surgical procedure is intended to allow the body tissues to react more favorably to surgical stress and reduce early postoperative pain.
The primary hypothesis is that continuous infusion of a local anesthetic along the edges of the mesh near the transabdominal fixation sutures and spiral tacks placed to secure mesh to the anterior abdominal wall will both subjectively and objectively improve postoperative pain control following laparoscopic ventral hernia repair. A secondary hypothesis is that pulmonary function and bowel function postoperatively will recover faster with the use of a continuous infusion of local anesthetic.
- Conditions
- Hernia, Ventral
- Being tested
- bupivacaine, On-Q PainBuster pump
- Keywords
- Hernia, Ventral, Laparoscopic Hernia Repair
- Medical subject headings
- Hernia, Ventral, Hernia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bupivacaineDrug
Also called Marcaine
administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
On-Q PainBuster pumpDevice
local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
| Study group | Role | What they receive |
|---|---|---|
| Bupivicaine via Elastomeric pump | Active comparator | Bupivicaine via elastomeric pump Receives: Drug: bupivacaine |
| Placebo via elastomeric pump | Placebo comparator | Placebo via elastomeric pump Receives: Device: On-Q PainBuster pump |
What is being measured
The primary outcome is the main question the study is designed to answer.
Place an elastomeric infusion catheter superficial to the mesh at the conclusion of the laparoscopic ventral hernia repair and compare the following to a group that receives a placebo infusion of saline:
Measured: 3 months
Measuring: Visual Analog Pain Scale, Short-Form McGill Pain Questionnaire, Present Pain Intensity, Quantity of narcotic consumption
Measured: 3 months
Secondary outcomes (2)
Assess differences in postoperative pulmonary mechanics between the treated and nontreated groups by measuring the changes in maximal inspiratory volumes from baseline.
Measured: 3 months
The return of bowel function: Day of Flatus, Tolerating Regular Diet, Length of hospital stay
Measured: 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2007 (estimated)
- Study startDec 2005
- Primary completionDec 2007
- Study completionDec 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hernia, VentralStudies of the same condition, open and under way.
- More trials run by University Hospitals Cleveland Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michael J. Rosen, MD., University Hospitals Cleveland Medical Center
- Investigators
- Michael J. Rosen, MD, Principal investigator, University Hospitals Cleveland Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00472134
- Sponsor's protocol ID
- 11-05-22
- Status last verified
- Jan 2012
- First submitted
- 10 May 2007
- Last updated
- 8 Jun 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective, Randomized, Double-blind Trial of Continuous Infusion of 0.5% Bupivacaine be Elastomeric Pump for Prospective Pain Management After Laparoscopic Ventral Hernia Repair.
- ClinicalTrials.gov ID
- NCT00472134
- Acronym / sponsor ID
- 11-05-22
- Conditions
- Hernia, Ventral
- Keywords
- Hernia, Ventral, Laparoscopic Hernia Repair
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- University Hospitals Cleveland Medical CenterUniversity, hospital or other
- Study start
- Dec 2005
- Primary completion
- Dec 2007 (actual)
- Study completion
- Dec 2007 (actual)
- First posted
- 11 May 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the effects of a local anesthetic dispensed via a tiny catheter device, called the ON-Q PainBuster pump, placed during surgery on top of the mesh used in the laparoscopic repair of ventral hernias. The goals are:
- reducing postoperative pain from this procedure
- decreasing length of hospital stay
- reducing or eliminating amount of post-operative narcotics used
Detailed description
One outcome of the greater than 2 million abdominal operations performed in the United States each year is an incisional hernia rate of 3% to 20%. As a result, approximately 150,000 ventral hernia repairs are performed annually. The increasing number of incisional hernias merely reflects the evolution of surgery with the ability to perform larger abdominal operations such as aortic surgery and colectomy. Primary tissue repairs have had unacceptable rates of recurrence when used for larger defects. The introduction of prosthetic biomaterials revolutionized hernia surgery with the concept of a tension-free repair. The subsequent rate of recurrence has been lowered to less than 10%. However, the required dissection of wide areas of soft tissue for mesh placement contribute to an incidence of wound infections and wound-related complications of 12% or greater. These problems were part of the impetus to develop minimally invasive techniques for ventral herniorrhaphy.
The laparoscopic repair of ventral hernias is rapidly evolving with patient and surgeon interest in less morbid herniorrhaphies and the appeal of minimally invasive surgery. The technique is based on the open, preperitoneal repair described by Rives and Stoppa. The placement of a large mesh in the preperitoneal location allows for an even distribution of forces along the surface area of the mesh, which may account for the strength of the repair and the decreased recurrence rates associated with it. The minimally invasive approach embraces the concept that a retromuscular mesh repair may be more durable, although the mesh is placed one layer deeper on an intact peritoneum in comparison to the open technique. The technique incorporates other fundamental components of the open repair such as wide mesh overlap of the defect and the use of transabdominal fixation sutures and spiral tacks to secure the mesh.
While the laparoscopic approach to ventral hernia repair has been documented as safe and effective, with low recurrence rates and minimal patient morbidity, some patients complain of significant post-operative pain for up to 1-3 months after surgery. The exact cause of this postoperative discomfort has not been clearly elucidated. Several hypotheses exist. Some feel that the extensive adhesiolysis required for incisional hernia repair causes significant peritoneal irritation that is exacerbated with the placement of intraperitoneal mesh. Others implicate the spiral tacks placed through the mesh into the peritoneum as sources of persistent discomfort. While others feel that the transabdominal fixation sutures are the localizing site for the accompanying postoperative pain. Transabdominal suture site pain after laparoscopic ventral hernia repair is not uncommon, and occurred in 23% of patients in one series.8 The transabdominal fixation suture sites are those incisions where sutures are placed to secure the mesh placed during laparoscopic ventral hernia repair to the anterior abdominal wall. The sutures are placed in a "clockwise" manner approximately every 4 to 5 cm at the periphery of the mesh as well as 5 mm spiral tacks to hold it in place until fibrocollagenous ingrowth secures the mesh to the abdominal wall. This persistent abdominal pain has been documented as a minor long-term complication resulting from laparoscopic ventral hernia repair, but it can be troublesome for patients in the immediate postoperative period.
The most effective method for managing this postoperative pain has not been defined.
The goal of postoperative care is to minimize the amount of pain a patient experiences following surgery and to help the patient make a quick recovery that leads to a shorter hospital stay free of complications and an earlier return to self-reliance. The most common treatment for pain after operation is opioid analgesic drug administration. Opioids are associated with undesirable side effects such as respiratory depression, nausea and vomiting, itching, increased duration of postoperative ileus, and delay in discharge. These side effects can be decreased with a reduction in the amount of opioid drugs utilized. Additionally, systemic narcotics may not optimize pain management in a specific region of the body because of its centralized effect. This may lead to a decreased mentation, reduced mobility, and a slower return to normal activities. Because a reduction of the daily consumption of narcotics is often associated with a decrease in analgesia, many other treatments for postoperative pain have been evaluated. For example, epidural analgesia is effective but the catheter needs to be placed preoperatively, is fairly invasive method, and the maintenance of the epidural treatment can be time consuming and expensive. Many studies have found clinical pain management benefits to the use of local analgesia, as measured by the use of less post-operative pain medication and more favorable ratings on pain intensity scales. Recently, a new method of delivering continuous wound infiltration with a solution of local anesthetic through an indwelling irrigation apparatus has been used in an attempt to reduce early postoperative discomfort in patients after thoracotomy, donor nephrectomy, and open inguinal hernia repair. These prospective randomized double blind studies universally report decreased postoperative discomfort and limited usage of opioids with the usage of these novel catheters.
In this study, the goal is to minimize postoperative pain so that post-operative narcotic requirements will be unnecessary or required less frequently. The infusion of a local anesthetic immediately following the surgical procedure is intended to allow the body tissues to react more favorably to surgical stress and reduce early postoperative pain.
The primary hypothesis is that continuous infusion of a local anesthetic along the edges of the mesh near the transabdominal fixation sutures and spiral tacks placed to secure mesh to the anterior abdominal wall will both subjectively and objectively improve postoperative pain control following laparoscopic ventral hernia repair. A secondary hypothesis is that pulmonary function and bowel function postoperatively will recover faster with the use of a continuous infusion of local anesthetic.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bupivicaine via Elastomeric pump | Active comparator | Drug: bupivacaineBupivicaine via elastomeric pump |
| Placebo via elastomeric pump | Placebo comparator | Device: On-Q PainBuster pumpPlacebo via elastomeric pump |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Laparoscopic ventral hernia repair
- Consent obtained
Key exclusion criteria (8 listed)
- Under 18 years
- Allergic to Bupivacaine
- significant liver or renal disease
- Contraindication to PCA
- Current daily opioid usage
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bupivacaineAlso: Marcaineadministered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h. | Drug | Bupivicaine via Elastomeric pump |
| On-Q PainBuster pumplocal anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days | Device | Placebo via elastomeric pump |
Primary outcome
Place an elastomeric infusion catheter superficial to the mesh at the conclusion of the laparoscopic ventral hernia repair and compare the following to a group that receives a placebo infusion of saline:
Time frame: 3 months
Measuring: Visual Analog Pain Scale, Short-Form McGill Pain Questionnaire, Present Pain Intensity, Quantity of narcotic consumption
Time frame: 3 months
2 secondary outcomes
Assess differences in postoperative pulmonary mechanics between the treated and nontreated groups by measuring the changes in maximal inspiratory volumes from baseline.
Time frame: 3 months
The return of bowel function: Day of Flatus, Tolerating Regular Diet, Length of hospital stay
Time frame: 1 week
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2015.
Related trials for Hernia, Ventral
Recruiting
Duramesh Versus Minimally Invasive IPOM for High-Risk Umbilical Hernia Repairs
Umbilical Hernia, Ventral Hernia
Active, not recruitingObservational study
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
Hernia, Ventral, Hernia Incisional
Recruiting
GORE® ENFORM Biomaterial Product Study
Hernia, Ventral, Hernia, Hiatal
RecruitingPhase 4
Preoperative BOTOX® Injection for Large Ventral Hernia Repair
Hernia Abdominal Wall, Botox Injection
Not yet recruiting
SUTURE TYPE AND RECURRENCE RISK AFTER INCISIONAL HERNIA REPAIR
Ventral Incisional Hernia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael J. Rosen, MD principal investigator
University Hospitals Cleveland Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing bupivacaine and On-Q PainBuster pump in people with Hernia, Ventral, run by University Hospitals Cleveland Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jun 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Place an elastomeric infusion catheter superficial to the mesh at the conclusion of the laparoscopic ventral hernia repair and compare the following to a group that receives a placebo infusion of saline: (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2015.